LENSAR, Inc.

NASDAQ:LNSR

Medical - Devices

Healthcare
$4.85 -8.15%

-$0.51 today

Market cap
$59.63M
Beta
0.87
P/E (TTM)
2.4
EPS (TTM)
$2.42
52W Low $5.06High $13.47

Volume 0.06M

Average 0.09M

LNSR Interest Income

Income earned on cash, deposits, and investments held by the company.

LENSAR, Inc.NASDAQ: LNSR

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $19K fell 26.9% year over year, ahead of the -36.6% change in trailing-twelve-month interest income. Sequentially, it fell 17.4% from the prior quarter. Over 3 fiscal years it compounded at +74.9% a year.

Context

  • Interest income amounted to 0.2% of revenue in FY2025, unchanged from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -26.9% holds above the trailing-twelve-month pace of -36.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19K-17.4% QoQ
Last fiscal yearDec 2025
$91K-11.7% YoY
LTMMar 2026
$64K-36.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.9%——
1 year-11.7%——
3-year CAGR+74.9%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
91K USD
Year-over-year change
-11.7%
4-year CAGR
+27.9%

Interest Income vs competitors

How LNSR compares with its peers on the latest reported figures

  • LNSR's LTM Mar 2026 interest income of $64K is the 7th highest of the 10 companies compared; the peer median is $1M.
  • Its year-over-year change of -36.6% is the 6th highest of 9, against a peer median of -28.8%.
  • Interest income amounts to 0.1% of revenue for LNSR, versus a peer median of 2.8%.
LNSR Competitors Peer median
Interest Income for LNSR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MXCTMaxCyte, Inc.LTM Mar 2026$6.67M -29.3%+22.9%20.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$5.25M -28.4%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.67M -18.5%+25.2%508.4%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$1.44M -45.8%-5.3%4.2%
PROFProfound Medical Corp.LTM Mar 2026$1M +2525.1%+1.2%5.3%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$645K +67.1%+45.5%1.4%
LNSRLENSAR, Inc.LTM Mar 2026$64K -36.6%+74.9%0.1%
AVRAnteris Technologies Global Corp.LTM Mar 2026$0 —+49.9%0.0%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
OWLTOwlet, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding LNSR) $1M-28.8%+24.0%2.8%

Competitors are the stored peer set for LNSR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.46M35.36M42.16M53.49M58.44M
Cost of Revenue16.63M15.4M21.06M27.64M31.31M
Gross Profit17.83M19.96M21.11M25.85M27.12M
Gross Margin51.8%56.4%50.1%48.3%46.4%
Research & Development12.36M11.81M6.14M5.33M5.62M
Selling, General & Admin23.89M27.17M26.1M26.49M45.16M
Operating Expenses37.49M40.13M33.34M36.52M51.7M
Depreciation & Amortization2.76M3.41M3.52M3.93M4.5M
EBITDA(16.84M)(16.51M)(10.87M)(3.01M)(29.78M)
EBITDA Margin-48.9%-46.7%-25.8%-5.6%-51.0%
Operating Income(19.65M)(20.18M)(12.23M)(10.67M)(24.58M)
Operating Margin-57.0%-57.1%-29.0%-19.9%-42.1%
Interest Income34K17K85K103K91K
Interest Expense00000
Other Income / Expenses51K263K(2.15M)(20.74M)(9.7M)
Income Before Tax(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Pre-Tax Margin-56.9%-56.3%-34.1%-58.7%-58.7%
Income Tax Expense00000
Net Income(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Net Margin-56.9%-56.3%-34.1%-58.7%-58.7%
EPS (Basic)(2.10)(1.96)(1.31)(2.73)(2.87)
EPS (Diluted)(2.10)(1.96)(1.31)(2.73)(2.87)
Weighted Avg Shares9.37M10.16M10.97M11.52M11.96M
Weighted Avg Shares (Diluted)9.37M10.16M10.97M11.52M11.96M

LENSAR, Inc.

NASDAQ:LNSR

Intrinsic Alpha fair value

Locked

Current Price

$4.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.